Compared benefits and risks of muscle related disease of statins with evidence to evidence / 中国药学杂志

ABSTRACT

This paper reviewed benefit and risk of myopathy and rhabdomyolysis in statins with guide and following the medical evidence. The chemical structure of statins is closely related to the effect and heterogeneity of the drugs. The use of statins including atorvastatin, rosuvastatin can give patients more clinical benefit when strengthen to low blood lipid. Although rosuvastatin in statins is strongest, but presence of sulphonamide group resulted in the increase of its toxicity, It show that rosuvastatin risk for rhabdomyolysis was significantly higher than that of atorvastatin statins by foreign evidence. Therefore, the patients following with multiple risk factors need to use caution with the choice of rosuvastatin. Recently rosuvastatin causing myopathy and rhabdomyolysis cases in the world has increased, It should arouse the attention of clinical. Clinical pharmacists should focus more on pathophysiological state, interaction, drug genome science to proceed, so we can summarize and analyze the occurrence regularity, and investigate its mechanism in order to protect the safety of patients with medication. It can help clinical pharmacists to take responsibility for the uprising.